Delving into the Latest Updates on Basiliximab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Basiliximab (Genetical Recombination), Basiliximab (USAN/INN), Basiliximab (genetical recombination) (JAN)

+ [13]

Target

IL2RA

Action

inhibitors

Mechanism

IL2RA inhibitors(Interleukin-2 receptor alpha chain inhibitors)

Therapeutic Areas

Immune System Diseases

Active Indication

Renal transplant rejectionGraft Rejection

Inactive Indication

Alpha 1-Antitrypsin DeficiencyBronchiolitis ObliteransColitis, Ulcerative+ [3]

Originator Organization

Novartis Pharma AG

Active Organization

Novartis Europharm Ltd.Novartis Pharma AGNovartis Pharma Schweiz AG

+ [1]

Inactive Organization

Cerimon Pharmaceuticals, Inc.

Novartis AG

Drug Highest PhaseApproved

First Approval Date

United States (12 May 1998),

Graft Rejection

RegulationOrphan Drug (Japan)

Login to view timeline

Structure/Sequence

Sequence Code 616716476H

Source: *****

Sequence Code 616716477L

Source: *****

This trial is to compare the risk/benefit profile over six-month follow-up of two induction immunosuppressive regimens based on one or seven low-dose perioperative RATG infusions on top of the same induction therapy with basiliximab and steroid (progressively tapered post-transplant) and maintenance therapy with calcineurin inhibitors and mycophenolate mofetil/mycophenolic acid in 75 recipients (25 Patients and 50 Reference-Patients) of a single or dual first kidney transplant from an ideal or marginal donor at a single Renal Transplant Center.

Start Date30 Jul 2024

Sponsor / Collaborator-

NCT06480630

/ Not yet recruitingPhase 2IIT

Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases

Evaluating the safety and effectiveness of a CD25 monoclonal antibody-based prophylactic acute graft-versus-host-disease (aGVHD) regimen following unrelated umbilical cord blood transplantation (UCBT) for malignant hematologic disorders in reducing severe aGVHD.

Start Date01 Jul 2024

Sponsor / Collaborator

Anhui Provincial Hospital

JPRN-UMIN000053362

/ RecruitingNot ApplicableIIT

Nationwide survey on the use of basiliximab (genetical recombination) for prevention of acute rejection after transplantations - Nationwide survey on the use of basiliximab (genetical recombination) for prevention of acute rejection after transplantations

Start Date01 Feb 2024

Sponsor / Collaborator-

100 Clinical Results associated with Basiliximab

Login to view more data

100 Translational Medicine associated with Basiliximab

Login to view more data

100 Patents (Medical) associated with Basiliximab

Login to view more data

1,877

Literatures (Medical) associated with Basiliximab

01 Mar 2025·Transplant Immunology

Induction outcomes in adult kidney transplantation: Two decades of UNOS data analysis

Article

Author: Faddoul, Geovani ; Aydin-Ghormoz, Emmanuel ; Ortiz, Jorge ; Li, Meng-Hao ; Schubauer, Kathryn ; Koizumi, Naoru

OBJECTIVESIn the US, 92 % of kidney transplant recipients are treated with induction therapy. This analysis assesses the impact of induction immunosuppression on outcomes such as graft failure, patient mortality, and length of hospitalization.MATERIAL AND METHODSRetrospective analysis of the UNOS database in adults who received a kidney transplant from January 2000 to June 2022. Analysis focused on induction regimens including anti-thymocyte globulin (ATG), alemtuzumab and basiliximab with maintenance immunosuppression of calcineurin inhibitors, mycophenolate with or without prednisone. Multivariable logistic regression was performed to identify factors correlating with outcomes. Kaplan-Meier product limit method assessed survival.RESULTSAlemtuzumab correlated with increased graft failure in deceased-donor and living-donor kidney transplants (HR 1.075 [1.015-1.138] p = 0.013 and HR 1.096 [1.011-1.188] p = 0.026 respectively) and with increased mortality in living-donor kidney transplants (HR 1.215 [1.107-1.332] p < 0.001). Steroids maintenance was associated with fewer acute rejections in both deceased-donor and living-donor kidney transplants (HR = 0.875 [0.84-0.90] p < 0.001 and HR = 0.88 [0.83-0.93] p < 0.001 respectively). Odds of CMV was lower with alemtuzumab. Induction with alemtuzumab was associated with shorter length of stay in both deceased-donor and living-donor kidney transplants and longer time to first hospitalization in living-donor kidney transplants compared to ATG.CONCLUSIONSAlemtuzumab correlated with shorter length of stay, fewer re-hospitalizations and less CMV infections. However, it was associated with higher odds of graft failure and mortality in adult kidney transplant recipients.

01 Feb 2025·Pediatric Transplantation

First ABO‐Incompatible Pediatric Kidney Transplant in South Africa—A Case Report

Article

Author: Thomson, Dave ; McCulloch, Mignon I. ; Nourse, Peter ; Du Toit, Tinus ; Barday, Zunaid A. ; Ndamase, Bongiswa ; Siyothula, Thozama ; Abdo, Theresa ; Pienaar, Taryn ; Coetzee, Ashton

ABSTRACTBackgroundBlood group incompatibility previously represented an obstacle to living related donor (LRD) options; desensitization modalities have expanded LRD options. ABO‐incompatible kidney transplants have been successful in adults and pediatric liver transplants, but to date not yet in pediatric kidney transplants in South Africa.Case ReportPatient X is a 5 year old male with end‐stage kidney failure due to Posterior Urethral Valves, requiring peritoneal dialysis pre‐transplant. His sister was the only suitable LRD. The recipient was blood group A+; donor was blood group B+; HLA match was 5/10, nil HLA donor specific antibodies and negative CDC and Flow crossmatches. The recipients' anti‐B titer pre‐transplant was a maximum of 1:8. A pre‐emptive desensitization dose of Rituximab (375 mg/m2) was administered 4 weeks before transplant. The anti‐B titer decreased to 1:2 following the Rituximab (CD19% of 0%). Post‐transplant, the Anti‐B titers were monitored for the first 10 days, with a maximum titer of 1:8 (immunoadsorbtion therapy available if > 1:16, or if associated graft dysfunction). Immunosuppressant protocol consisted of Basiliximab, Tacrolimus, Azathioprine, and Prednisone. Post‐transplant, the creatinine improved to 60–70 μmol/L at Week 1. 7 weeks post‐transplant, serum creatinine increased > 10% with an antibody titer of 1:2. Kidney biopsy showed CNI‐related toxicity; renal function improved with reduction in Tacrolimus doses. Kidney function remains stable 1‐year post‐transplant with nil episodes of rejection.ConclusionThis is the first ABO‐incompatible kidney transplant in a pediatric patient in South Africa and represents an important step in expanding the pool of potential living related donors.

01 Feb 2025·Journal of the Science of Food and Agriculture

Fabrication, characterization and simulated gastrointestinal digestion of sea buckthorn pulp oil microcapsule: effect of wall material and interfacial bilayer stabilization

Article

Author: Ma, Chuan‐Guo ; Ma, Yan ; Zhao, Man ; Chen, Xiao‐Wei ; Xianqing, Huang ; Bai, Ge

AbstractBACKGROUNDSea buckthorn (Hippophae rhamnoides L.) pulp oil is rich in functional components; however, low water solubility and stability limit its applications. This study fabricated sea buckthorn pulp oil microcapsules using whey protein isolate (WPI), soy protein isolate (SPI), sodium caseinate (NaCN), gum arabic (GA), starch sodium octenylsuccinate (OSAS) and SPI mixed with chitosan (CHI). The influences of these wall materials on physicochemical properties, release behavior and digestibility were explored.RESULTSProtein‐based wall materials (WPI, NaCN, SPI) demonstrated lower bulk densities due to their porous structures and larger particle sizes, while GA and OSAS produced denser microcapsules. Encapsulation efficiency was the highest for protein‐based microcapsules (79.41–89.12%) and the lowest for GA and OSAS. The surface oil percentage of protein‐based microcapsules (1.41–4.40%) was lower than that of the other microcapsules. Protein‐based microcapsules showed concave and cracked surfaces, while GA and OSAS microcapsules were spherical and smooth. CHI improved reconstitution performance, leading to faster dissolution. During simulated gastrointestinal digestion, protein‐based microcapsules released more free fatty acids (FFAs) in the intestinal phase, while CHI‐modified SPI microcapsules showed a delayed release pattern due to thicker walls.CONCLUSIONProtein‐based wall materials were more effective for sea buckthorn pulp oil microencapsulation, providing higher encapsulation efficiency, better flow properties and releasing more FFAs. The addition of CHI led to the layer‐by‐layer self‐assembly of the microcapsule wall and resulted in sustained release during in vitro intestinal digestion. These findings suggested the potential of protein‐based microcapsules for targeted delivery and improved applications of bioactive oils in the food industry. © 2024 Society of Chemical Industry.

100 Deals associated with Basiliximab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03058	Basiliximab	L04AC02	DB00074

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Renal transplant rejection	Iceland	Novartis Europharm Ltd.	09 Oct 1998
Renal transplant rejection	Liechtenstein	Novartis Europharm Ltd.	09 Oct 1998
Renal transplant rejection	Norway	Novartis Europharm Ltd.	09 Oct 1998
Renal transplant rejection	European Union	Novartis Europharm Ltd.	09 Oct 1998
Graft Rejection	United States	Novartis Pharmaceuticals Corp.	12 May 1998

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kidney Failure, Chronic	Preclinical	United States	Novartis AG	01 May 2009
Colitis, Ulcerative	Preclinical	Czechia	Cerimon Pharmaceuticals, Inc.	01 Jan 2007
Colitis, Ulcerative	Preclinical	United States	Cerimon Pharmaceuticals, Inc.	01 Jan 2007
Colitis, Ulcerative	Discovery	Czechia	Cerimon Pharmaceuticals, Inc.	01 Jan 2007
Colitis, Ulcerative	Discovery	United States	Cerimon Pharmaceuticals, Inc.	01 Jan 2007
Colitis, Ulcerative	Discovery	Slovakia	Cerimon Pharmaceuticals, Inc.	01 Jan 2007
Alpha 1-Antitrypsin Deficiency	Discovery	Canada	Novartis AG	01 May 2004
Bronchiolitis Obliterans	Discovery	Canada	Novartis AG	01 May 2004
Hepatitis C	Discovery	-	Novartis AG	01 Dec 2002
Graft Rejection	Discovery	-	Novartis AG	01 May 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISN WCN2024	Not Applicable	Glomerulonephritis, IGA	40	Basiliximab induction	vhlupamuzh(umauktvdil) = 55% patients lost their graft with an average time to graft loss of 8.2 years. Graft loss at 1, 5 and 10 years was 2%, 18% and 38% respectively. The use of steroids was associated with a trend to delayed graft loss, although this was statistically insignificant. There is no association between duration of steroid therapy and time to graft loss gntmmqjyik (mjxzizkmux ) View more	Positive	01 Apr 2024
				Alemtuzumab induction
Tandem Meetings ASTCT and CIBMTR2024 Manual	Not Applicable	Refractory Acute Graft Versus Host Disease	92	Basiliximab	(pgaecbkmrp) = oeivcjphlu uarhdsvave (jgbnempstv ) View more	Positive	01 Feb 2024
ASH2023	Not Applicable	Steroid Refractory Graft Versus Host Disease	60	Basiliximab and Infliximab	(kzmttndlbf) = ijywnrmbco xntznbxcus (dfuwapjoud ) View more	-	11 Dec 2023
EHA2023	Not Applicable	Chronic graft-versus-host disease Second line	20	Basiliximab treatment	(zzrjgktggw) = pczshqkwvj wmwdrrlsrv (zdtuqwkogw ) View more	-	08 Jun 2023
				BASILIXIMAB (Control group)	(zzrjgktggw) = plqkddiyjk wmwdrrlsrv (zdtuqwkogw ) View more
NCT02123108 (CTgov)	Phase 4	-	59	Basiliximab+Tacrolimus+Mycophenolic Acid (Basiliximab)	sxuguywqlz(tlzlznskch) = cegzpprqdv jgccnelfbu (gtigposcnd, jkjnefekly - vthbfnebjm) View more	-	29 Sep 2022
				Tacrolimus+Mycophenolic Acid (Tacrolimus Group)	sxuguywqlz(tlzlznskch) = wtrewspnth jgccnelfbu (gtigposcnd, gfiljyaznf - vzcvrctmbg) View more
NCT02366728 (ELEVATE, CTgov)	Phase 2	Glioblastoma Multiforme \| Tetanus	64	111In-labeled DCs+Temozolomide+Human CMV pp65-LAMP mRNA-pulsed autologous DCs+saline (Group I: Unpulsed DC Pre-conditioning)	(mlnojfiqrs) = dqwgdowvsa iuxlxulalh (bnyeiyboda, fhnvflsbqj - frhguvsucd) View more	-	01 Feb 2022
				111In-labeled DCs+Temozolomide+Human CMV pp65-LAMP mRNA-pulsed autologous DCs+saline (Group II: Tetanus Pre-conditioning)	(mlnojfiqrs) = acyjmenfdg iuxlxulalh (bnyeiyboda, xpuweferjo - doifxeljch) View more
NCT02921789 (Phase 2a, CTgov)	Phase 2	Glomerulosclerosis, Focal Segmental	67	Methylprednisone+Prednisone+Basiliximab+Tacrolimus Capsules+Bleselumab	bobnrobrfm(hiftnqjacy) = jkyvyjvjfs wpftodmncj (nykirvgofc, jjblfrhwwq - lrijwkyrjn) View more	-	05 Jan 2022
ASN2021	Not Applicable	HLA mismatch	-	Thymoglobulin	jlpnzbdvmh(kezbcbuiqu): coefficient = -0.229 (95% CI, -0.508 to 0.049), P-Value = 0.106 View more	Positive	27 Oct 2021
				Basiliximab
MO999 (ERA2021)	Not Applicable	Renal transplant rejection	-	Basiliximab induction	(yfjofgxquq) = iulpimrmxw laqhcrlzky (ckewctyrvm ) View more	Positive	29 May 2021
MO982 (ERA2021)	Not Applicable	Panel Reactive Antibody (PRA)	-	Basiliximab	ipdqakdxnk(pgofxmziqw): OR = 1.17 (95% CI, 0.34 - 3.95), P-Value = 0.79	-	29 May 2021
				R-ATG

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data